Life Science Knowledge Bank
Drug Discovery System
LSKBã¯ã¯ã©ãŠãããŒã¹ã®åµè¬ã®ããã®ã¿ãŒã²ããæ¢çŽ¢ã·ã¹ãã ã§ãçŸæ£ããã®ã¿ãŒã²ããæ¢çŽ¢ãå§ããååç©æ§é ããã®ã¿ãŒã²ããäºæž¬æ©èœãæã¡ããã©ãã°ã»ãªããŒãã·ã³ã°ãå§ããäœçšæ©åºã®è§£éãæ¯æ§æ
å ±ã®åç
§ãªã©ã®æ©èœãæããŠããŸãã
æç®ã®è§£éã«ã¯AIãå©çšãçŸæ£ãšã¿ãŒã²ããã®é¢ä¿ãã°ã«ãŒãåããŠãããŸããŸãªè§åºŠã§æ¢ç¥æ
å ±ããç¹åŸŽãæœåºããŠããŸãã
-
ã¿ãŒã²ããããã€ãªããŒã«ãŒã®æ¢çŽ¢
-
ååç©ããã®ã¿ãŒã²ããäºæž¬
-
ãã©ãã°ã»ãªããŒãã·ã³ã°
-
æ¯æ§ãå®å šæ§æ å ±ã®åç §
-
âã¯ãŒã¯ãããŒããŒã«ã§åŠçã®èªåå
â ãçŸæ£ãããã¿ãŒã²ããã»ãã€ãªããŒã«ãŒã»åè£æ²»çè¬ãæ¢çŽ¢
Target Exploration
çŸæ£ããå¹çããã¿ãŒã²ãããæ¢çŽ¢
Biomarker Exploration
çŸæ£ããBiomarkeråè£éºäŒåãæ¢çŽ¢
GO-MoA
çŸæ£ã¿ãŒã²ãããšè¬å€ã®çç©åŠçæ©èœãå©çšããŠçŸæ£ããæ°èŠååç©ãæ°èŠã¿ãŒã²ãããæ¢çŽ¢
ããŸããŸãªææ³ã§æ¢çŽ¢ããçµæã®å ±éé ãæ±ãããã®ãç¹åŸŽã§ãã
â ãååç©ããã¿ãŒã²ããäºæž¬
Target Prediction
ååç©æ§é ããæ§é é¡äŒŒæ§ãšã¢ãã»ã€ããŒã¿ãå©çšããŠã¿ãŒã²ãããäºæž¬
Novel Target Estimation
by Protein Similarity
ã¿ã³ãã¯è³ªã®é¡äŒŒæ§ãå©çšããŠã¿ãŒã²ããåè£ç¯å²ãåºããŠæ¢çŽ¢
å éå¹³åã«ãã£ãŠã¿ãŒã²ãããäºæž¬ãããã«ãã±ããé¡äŒŒæ§ã¿ã³ãã¯è³ªãæ±ããç¯å²ãåºããŠæ¢çŽ¢
â ããã©ãã°ã»ãªããŒãã·ã³ã°
Drug Repurposing
çŸæ£ãæ¢åååç©ããæ°ããåè£ãæ¢çŽ¢
(A) æ§é ããã®ã¿ãŒã²ããäºæž¬ãšãã¿ã³ãã¯è³ªé¡äŒŒæ§ã«ããæ¡å€§ããæ°ããªçŸæ£ã®ã¿ãŒã²ãããæ¢çŽ¢ããã«ãŒã
(B) çŸæ£ãšãã®æ²»çè¬ã®çç©åŠçæ©èœãå©çšããŠæ°èŠã¿ãŒã²ãããæ¢çŽ¢ããã«ãŒã
ããŸããŸãªææ³ã§æ¢çŽ¢ããçµæã®å ±éç¹ãæ±ãã
â ãæ¯æ§æ å ±åç §
Toxicity associated Targets
Evidenceãšãšãã«Hepatotoxicityã«é¢ããã¿ãŒã²ããããªã¹ãã¢ããããäŸ
Liver toxicity/Adverse Event Information
Rosiglitazoneã®Liver toxicity衚瀺äŸ
â ãéºäŒåçºçŸå®éšããæ¯æ§è¡šçŸåäºæž¬ã»äœçšæ©åºäºæž¬
Expression Analysis
éºäŒåçºçŸè§£æã«ãã MoAïŒäœçšæ©åºïŒãå åšããæ¯æ§ã瀺åãã
çºçæ¯æ§ã«é¢ããGSEAããŒã¿ã»ãããæã£ãŠããããšãç¹åŸŽã
âãã®ä»ãMoAãªã©ã®ããŒã¿ã»ãããæºåããŠããã
ãŒãã©ãã£ãã·ã¥ã®çºçæ¯æ§ã®äºæž¬äŸ
â ãæ€çŽ¢ãã€ãã©ã€ã³æ§ç¯ããŒã«
Workflow
æšæºã¡ãã¥ãŒã«ãªãæ¢çŽ¢ãã€ãã©ã€ã³ãæ§ç¯å¯èœã
ç®çãšããããŒã¿åéãå¯èœã«ããèªåååŠçã
ç¹°ãè¿ã誰ã§ã䜿ããå®ååã
ããŒã¿ã®ã¢ããããŒãæãåå®è¡ã§æŽæ°ã
ååç©ã®éšåæ§é ãšãè€æ°ã®ã¿ãŒã²ããã¿ã³ãã¯è³ªãæå®ããå ¬å ±ããŒã¿ããååç©ã®æŽ»æ§å€ãšååéãããšã«ãææ決å®ãè¡ãããŒã«Elpis Mapã§è¡šç€ºãããã€ãã©ã€ã³ã®äŸ
æ©èœäžèŠ§
æ€çŽ¢ãã
Target Exploration
çŸæ£ããå¹çã®ããã¿ãŒã²ããæ¢çŽ¢
Biomarker Exploration
çŸæ£ããBiomarkeråè£éºäŒåãæ¢çŽ¢
GO-MoA
çŸæ£ã¿ãŒã²ãããšååç©ã®æ©èœãå©çšããŠçŸæ£ããååç©ãæ¢çŽ¢
Expression Analysis
éºäŒåçºçŸããŒã¿ããMoAïŒäœçšæ©åºïŒãæ¯æ§ãæ¢çŽ¢
Target Prediction
ååç©æ§é ããæ§é é¡äŒŒæ§ãå©çšããã¿ãŒã²ãããäºæž¬
Drug Repurposing
çŸæ£ããæ°ããªæ¢åè¬ãè¬å€ã®æ°èŠé©å¿çãæ¢çŽ¢
Novel Target Estimation by Protein Similarity
ã¿ã³ãã¯è³ªã®é¡äŒŒæ§ãå©çšããŠã¿ãŒã²ããåè£ç¯å²ãåºããŠæ¢çŽ¢
ããŒã«
Workflow
æèŒã®ããŒã¿ããŒã¹ãèªç±ã«æ€çŽ¢ã§ããã«ã¹ã¿ãã€ãºå¯èœãªæ€çŽ¢ãã€ãã©ã€ã³æ§ç¯ããŒã«
Elpis Map
HTSçã®ããŒã¿ãèŠèŠåã«ãããGO, No-Go, No-Needã®å€æããµããŒãããææ決å®æ¯æŽããŒã«
Venn Diagram
è€æ°ã®æ€çŽ¢çµæãããã³å³ãæžãæ©èœããã€ãªããŒã«ãŒæ¢çŽ¢ããã©ãã°ãªããŒãã·ã³ã°ãªã©è€æ°ã®çãã®å ±éé ç®ãåç §ããã®ã«æé©
åç §ãã
Toxicity & Side Effects
æ¯æ§ã«é¢é£ããã¿ãŒã²ããäžèŠ§è¡šç€º
ååç©ã®èæ¯æ§ãæ害äºè±¡ãåç
§
MoA (Mechanism of Action)
äœçšæ©åºãšã¿ãŒã²ãããçŸæ£ãååç©ãªã©ã®é¢ä¿æ å ±ãåç §
PDFã«ã¿ãã°ããŠã³ããŒã
æŠèŠçŽ¹ä»ãããªã¯ãã¡ããã
LSKB 8.0æŽæ°æ©èœçŽ¹ä»
AIã«ããèªç¶èšèªè§£éææ³ãšãGSEAã«çºçæ¯æ§ã®éºäŒåã»ãããè¿œå ããŸãã
AIã«ããèªç¶èšèªè§£éææ³ BERTãçšããçŸæ£ãšéºäŒåã®é¢ä¿æ§ãå©çšãããŒãã©ãã£ãã·ã¥ã«ããçæ®æ¯æ§è©Šéšãžã®ã¢ãããŒãã LSKB Ver. 8 ã®æ°æ©èœã«ã€ã㊠玹ä»ããŸãã
GOMoAæ©èœã®æŠèŠçŽ¹ä»
GoMoA
GOãšAIã§æœåºããMoAã䜿ããçŸæ£ããã¿ãŒã²ãããååç©ãæ¢ãæ¹æ³ã玹ä»ããŸããé©å¿æ¡å€§ã«ãå¿çšå¯èœã§ãã
Workflow ToolæŠèŠçŽ¹ä»
ã¯ãŒã¯ãããŒ
ç°¡åãªã¯ãŒã¯ãããŒã®æ§ç¯ãšå©çšæ¹æ³ãããªã»ããã¯ãŒã¯ãããŒã®å©çšæ¹æ³ã«ã€ããŠèª¬æããŸãã
LSKB 7.0 æŠèŠçŽ¹ä»
æŠèŠ
LSKB Ver7.0æŠèŠã«ã€ããŠã®èª¬æã§ãã深局åŠç¿ã䜿ã£ãMoAïŒäœçšæ©åºïŒãåŠçã®èªååã®ã¯ãŒã¯ãããŒãææ決å®æ¯æŽãäžå¿ã«çŽ¹ä»ããŸãã
äž»ãªæ©èœãšã¹ã¯ãªãŒã³ã·ã§ãã
From Disease
çŸæ£ããããããæ段ã§ã¿ãŒã²ãããååç©ãå¹çããæ¢ããŸãã
ã¡ã«ããºã ãããŒã¹ã«ã¿ãŒã²ãããšååç©ãæ€çŽ¢
G0ãšAIã§æœåºããç¬èªã®MoAãçµã¿åãããããããã®æ©èœãå©çšããæ°ããæ¢çŽ¢æ¹æ³ãæäŸãæ©èœããŒã¹ã®æ°ããæ¢çŽ¢æ¹æ³ã
çŸæ£ã®ã¿ãŒã²ãããã¯ã©ã¹åé¡è¡šç€º
ã¿ãŒã²ããããªã³ãããžãŒã¯ã©ã¹ã§åé¡è¡šç€ºããããšã§å¹çããçµã蟌ããã
ã¿ãŒã²ããã®è©³çŽ°ãšæŽ»æ§å€ã«çŽçµããã¢ãã»ã€æ å ±ãšååç©ãšãšãã«æŽ»æ§å€ãžã®å±éãå¯èœã
From Target (Gene or Protein)
ã¿ã³ãã¯è³ªãéºäŒåã®åšèŸºæ å ±ãå©çšããŠå¹çããã¿ãŒã²ãããæ¢çŽ¢
ã¿ãŒã²ããããæ²»çè¬ãååç©ãæ¢ã
è¬å€ãã¢ãã»ã€çµç±ã®ååç©ãã¢ãã»ã€åäœãSingle Protein Assay, Activityã§ã°ã«ãŒãåããŠèŠãããšãã§ããŸããè¬å€ã§ã¯ãMax Phase, Withdrawn, ATCãšãšãã«ãŸãšããŠããŸãã
é¢é£ååç©ã®èª¿æ»ã¯éºäŒåããè¡ããŸãããé¢é£ããã§ãããååç©ãåºãæ¢ããååç©åäœã§ã¢ãã»ã€ãGene Expression, MoA, Withdrawn, ATC, æç®ãªã©ã®æ å ±ãäžåºŠã«èŠãããšãã§ããŸãã
è¬å€ãAction Type, Max Phase, Withdrawn, ATCã®æ å ±ãšãšãã«åç §
åœè©²ã¿ã³ãã¯è³ªãã¿ãŒã²ãããšããã¢ãã»ã€ãã¢ãã»ã€åäœã§è¡šç€º
é¢é£ããã§ãããååç©ãåºãæ¢ããååç©åäœã§ã¢ãã»ã€ãGene Expression, MoA, Withdrawn, ATC, æç®ãªã©ã®æ å ±ãäžåºŠã«èŠãããšãã§ããŸãã
è¬å€ãAction Type, Max Phase, Withdrawn, ATCã®æ å ±ãšãšãã«åç §
ã¿ãŒã²ããããçŸæ£ãæ¢ã
âçŸæ£ãåPhaseæ¯ã«ã°ã«ãŒãåã§ããã®ã§ãã¿ãŒã²ããã«å¯ŸããŠçŸæ£åè£ãå¹ççã«
ïŒã€ã®æ¹æ³ã§è©äŸ¡ããé¡äŒŒã¿ã³ãã¯è³ªãåç §
Binding site, CD-HIT, Blast, RPS-Blast, DELTA-Blast ã®çµæãåé²
From Chemical
è±å¯ãªååç©ã¢ãããŒã·ã§ã³ãšæ©èœãããŒã¹ãšããåšèŸºæ å ±ã®æ¢çŽ¢
è¬çäœçšãMoAã代è¬é µçŽ ãé¡äŒŒååç©æ å ±ã®ååŸ
Phamacologyã§ã¯ãMoAé¢é£æ å ±ãšããŠãåãæ©èœãæã€è¬å€ãçŸæ£ã®åç §ã代è¬é µçŽ ãšã®é¢é£MoAã®è¬å€ãçŸæ£ãé¢é£ããååç©ãšããŠã¯ã代è¬ç©ã å¡©ã®çããååç©ãè±å¡©ããååç©ãªã©ããŸãšããŠèŠãããšãã§ããŸãã
ååç©ã®MoAãªã©ã®æ©èœãšé¢é£ä»£è¬ã¿ã³ãã¯è³ª
å¡©ã®çããååç©ãè±å¡©ããååç©ãªã©ã®é¡äŒŒã¿ã³ãã¯è³ª
ååç©ã®MoAãªã©ã®æ©èœãšé¢é£ä»£è¬ã¿ã³ãã¯è³ª
ååç©ãå©çšããå ¬å ±Gene ExpressionããŒã¿ã®åç §
Title Description èšèŒã® çŸæ£ãçµç¹ãååç©ãªã©ã®çšèªãšãã®å®éšã®å€åéºäŒå㧠æç®äžå ±éããã件æ°ãšæç®ãèŠãããšãã§ããŸãã
ååç©ãšçŸæ£ã®é¢ä¿ãåæããçµæã衚瀺
ååç©ãšçŸæ£ã®é¢ä¿ãGOãMoAãMax PhaseãClinical Trialãæç®ãåæããçµæããããªã¯ã¹è¡šç€ºã§äžåºŠã«èŠãããšãã§ããŸãã
ååç©ãå©çšããã¢ãã»ã€ã®çµæããŸãšããŠè¡šç€º
Assay, Activity, ADME, Toxicityãã°ã«ãŒãã§ãŸãšããŠã¿ãŒã²ãããšãšãã«è¡šç€ºã掻æ§å°ãã¢ãã»ã€ã¿ã€ããªã©ã§ã®å å®ãããã£ã«ã¿ãŒæ©èœãæç®ãåç §ã§ãã
ååç©æ§é ãå©çšããã¿ãŒã²ããã®äºæž¬
å éå¹³åã§ã¿ãŒã²ãããäºæž¬ããŸã
Rosiglitazoneããã®å éå¹³åã«ããã¿ãŒã²ããäºæž¬
ã¿ãŒã²ãããäºæž¬ããçµæ
èããããã¿ãŒã²ããã®æŽ»æ§å€ã®ãŸãšã
Rosiglitazoneããã®å éå¹³åã«ããã¿ãŒã²ããäºæž¬
WorkFlow Tool
LSKBã®ããŒã¿ããŒã¹ãæ倧éã«æŽ»çšã§ããæ¢çŽ¢ããŒã«
ã¿ãŒã²ãããååç©ãã¹ã¿ãŒãã«ãé¢é£æ å ±ãååŸ
ã¯ãŒã¯ãããŒããŒã«ã¯ãå€é¢çãªèŠçŽ ã«ããçµã蟌ã¿ãªã©è€éãªæ€çŽ¢ãç°¡åã«æ§ç¯ã§ãããã€åå©çšã§ããŸãã
ããŒã¿ããŒã¹ã®æ€çŽ¢ãæ€çŽ¢çµæã®ãã£ã«ã¿ãŒãªã©ãçµã¿åãããããšã§ãç®çã«åãããæ€çŽ¢ãããŒã¿ãã€ãã³ã°ãè¡ããŸãã
èšå®æžã¿ã®ã¯ãŒã¯ãããŒâãæºå
ã¯ãŒã¯ãããŒæ§ç¯ã«äŸ¿å©ãªäŸé¡ãæºåããã®ãŸãŸãå©çšã§ããŸããããããã®ã¯ãŒã¯ãããŒãå¿çšããŠãç¬èªã®ã¯ãŒã¯ãããŒã«äœãå€ããããšãç°¡åã§ãã
ã¯ãŒã¯ãããŒã®å©çšæ¹æ³ãããª
âç°¡åãªäœ¿ãæ¹ã®äŸããããªã§çŽ¹ä»ããŸãã
Workflow ToolæŠèŠçŽ¹ä»
Elpis Map
HTSããŒã¿ã®èŠèŠåã«ãããGO, No-Go, No-Needãå€æããããããææ決å®æ¯æŽããŒã«
ååéã®å€åã«äŒŽã掻æ§ã®å€åã®é¢ä¿ãèŠèŠå
ElpisMapã¯ãååç©ã®æ£åžå³ã®äžã«ãäŸãã° ååéã§3åå²ãã掻æ§å€ãªã©ã®å¥ã®ç¹åŸŽéã§åã°ã«ãŒãã®éå¿ãšãã®è»è·¡ã衚瀺ã§ããŸããããã«ããå ¥åããéåã ååéã®å¢å ã«äŒŽã 掻æ§ã®å¢åŒ·ãããŠããã容æã«å€æã§ãã ææ決å®ãµããŒãããŒã«ã§ãã
ããPIK3CGã®ã¢ãã»ã€ã«ãããŠ å ±ééšåæ§é ããã€ååç©ã®æŽ»æ§æ å ±äŸ
ããPIK3CGã®ã¢ãã»ã€ã«ãããŠ å ±ééšåæ§é ããã€ååç©ã®æŽ»æ§æ å ±ã«ã€ã㊠X軞㫠ååéãšY軞㫠掻æ§å€ã§ããããããŠããŸããã°ã¬ãŒã®â㯠ååé300æªæºã300以äž350æªæºã350以äžã§ã«ããŽãªãŒããããŠãã®éå¿ãããããããè»è·¡ãç¢å°ã§ç€ºããŠããŸãã
ããã«ãããã®éªšæ Œããã€ååç©ãååéã®å¢å ã«ãã ããPIK3CGã«å¯Ÿãã掻æ§å€ãåäžããããšãåãããŸãã
å ã®å ±ééšåæ§é ããã€ååç©çŸ€ã®ã¢ãã»ã€æ å ±ããåPIK3CAãPIK3CBãPIK3CGãPIK3CDã®æŽ»æ§å€ã§ããããããŠããŸããäžæ®µã® PIK3CGãPIK3CDã«å¯Ÿããçµæã¯ãã°ã¬ãŒã®â㯠ååé300æªæºã300以äž350æªæºã350以äžã§ã«ããŽãªãŒã«åå²ããã®éå¿ã®è»è·¡ãã㯠ååéå¢å€§ã«ãã㊠掻æ§ãäžæãããã®éªšæ Œã®ååç©ã»ãã㯠ãããã¿ãŒã²ããã«æå¹ã§ãããšç€ºåããããäžæ¹ äžæ®µã®PIK3CAãPIK3CBã«å¯Ÿããçµæã¯ãååéå¢å€§ã«ãã㊠掻æ§ãäœäžããŠãããæŽãªãæ§é å±éã§æŽ»æ§ã®åäžãå°é£ã§ããããšã瀺åããŠããŸãã
ååç©æ å ±ã®ããŒãã«è¡šç€º
PIK3CD ã® ããããã«ãããŠãèµ€ã§å²ãã 掻æ§å€ã®é«ããµãŒã¯ã«ãéžæããããšã§ãä»ã®ïŒã€ã®ããããã§ã éžæãããŠããããšãããããããã«Selected Itemã§ã«ãããŠéžæããååç©æ å ±ãããŒãã«ã§è¡šç€ºãããŠããŸãã
èšç®çµæã®ä¿å
èšç®çµæã¯ãæ¡ä»¶ãå«ããŠãšã¯ã¹ãããŒã©ãŒåœ¢åŒã®ç®¡çã§ä¿åã§ããŸãããŸããå°çšãã©ãŒãããã§ãšã¯ã¹ããŒãããå ±æããããšãå¯èœã§ãã